Radoslaw Kiesz, MD
Cardiovascular Disease · San Antonio, TXNPI 1710924675
Payments from drug & device makers
Across 242 payments — averaging $132.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$20K
- Amgen$2K
- Cardiovascular Systems Inc.$2K
- Biotronik Inc.$1K
- Boston Scientific$1K
- Medtronic$874
- plus $5K from 31 others
What the payments were for
- Royalty or licence$1,17913%
- Food & beverage$7,67886%
- Education$711%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 7 | $20,094 |
| Amgen | 15 | $2,253 |
| Cardiovascular Systems Inc. | 6 | $1,590 |
| Biotronik Inc. | 30 | $1,481 |
| Boston Scientific | 3 | $1,197 |
| Medtronic(2 entities) | 23 | $874 |
| Novartis | 30 | $645 |
| Abbott | 31 | $601 |
| Merck | 33 | $571 |
| Esperion Therapeutics, Inc. | 17 | $564 |
| Cardio Flow, Inc. | 1 | $307 |
| Angiodynamics, Inc. | 2 | $256 |
| Abiomed | 2 | $250 |
| Penumbra, Inc. | 1 | $235 |
| Cardinal Health 200 LLC | 3 | $231 |
| Irhythm Technologies, Inc. | 2 | $139 |
| Impulse Dynamics (USA) Inc. | 6 | $122 |
| Devoro Medical Inc. | 1 | $113 |
| Acist Medical Systems, Inc. | 3 | $73 |
| EKOS Corporation | 1 | $65 |
| Venclose Inc. | 1 | $59 |
| Cardiva Medical, Inc. | 2 | $50 |
| Amarin Pharma, Inc. | 3 | $50 |
| E.r. Squibb & Sons, L.L.C. | 3 | $41 |
| Regeneron Healthcare Solutions, Inc. | 2 | $38 |
| Shockwave Medical, Inc | 2 | $34 |
| Pfizer | 2 | $28 |
| Teleflex LLC | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Novo Nordisk | 1 | $21 |
| Braemar Manufacturing, LLC | 1 | $21 |
| W. L. Gore & Associates, Inc. | 1 | $19 |
| Heartflow, Inc. | 1 | $18 |
| Bard Peripheral Vascular, Inc. | 1 | $15 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $6 |
| Bardy Diagnostics, Inc. | 1 | $6 |
| Vantis Vascular, Inc. | 1 | $0 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RUNWAY$1,179
- Kerendia$375
- NEXLETOL$369
- Resolute$271
- Auryon Laser System 100-120 Vac$256
- Impella$250
- NEXLIZET$247
- LEQVIO$246
- Indigo System$235
- XIENCE SIERRA$164
- HawkOne$160
- Repatha$125
- EluNIR Radaforolimus Eluting Coronary Stent System$125
- ZIO XT Patch$118
- WOLF$113
- VERQUVO$112
How this compares
$32,115 in reported general payments places this provider in the 80th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 89 | $96,023 |
| Repatha SureclickEvolocumab | 78 | $88,553 |
| EntrestoSacubitril/Valsartan | 65 | $74,636 |
| VascepaIcosapent Ethyl | 27 | $17,132 |
| Praluent PenAlirocumab | 29 | $15,607 |
| XareltoRivaroxaban | 17 | $13,801 |
| VerquvoVericiguat | 11 | $13,297 |
| Rosuvastatin Calcium | 959 | $12,385 |
| Repatha SyringeEvolocumab | 20 | $10,829 |
| Candesartan Cilexetil | 76 | $4,074 |
| ClopidogrelClopidogrel Bisulfate | 471 | $3,778 |
| Metoprolol Succinate | 144 | $2,662 |
| Ranolazine ErRanolazine | 24 | $2,298 |
| Nebivolol Hcl | 25 | $1,575 |
| Carvedilol | 174 | $1,456 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $28 | $96,02389 claims |
| NovartisEntresto | $645 | $74,63665 claims |
| MerckVerquvo | $571 | $13,29711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in San Antonio
- Chandrasekhar KunavarapuSan Antonio$765K
- Robert SchnitzlerSan Antonio$425K
- Ramin Farzaneh-FarDallas$17.1M
- Jeffrey GladdenDallas$15.8M
- Ann NavarDallas$14.5M
- David BrabhamAmarillo$11.5M
- Justin GrodinDallas$6.2M
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- Faisal WahidMcKinney$3.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.